Mykén P S, Berggren H E, Larsson S, Roberts B, Wallentin I, Caidahl K
Department of Thoracic and Cardiovascular Surgery, Sahlgrenska University Hospital, Göteborg, Sweden.
J Thorac Cardiovasc Surg. 1998 Oct;116(4):599-608. doi: 10.1016/S0022-5223(98)70166-7.
Our objectives were to evaluate the long-term bioprosthetic and cardiac functional outcome after insertion (over a 10-year period) of a new-generation porcine zero pressure-fixed Biocor bioprosthesis, as well as to determine the echocardiographic accuracy for selection of patients requiring reoperation. The long-term systematic Doppler echocardiographic assessment after valve replacement with this bioprosthesis is lacking.
Between January 1983 and January 1993, we inserted 756 Biocor prostheses in the aortic (619) or mitral (137) positions. All 51 patients who had a reoperation during the follow-up time were evaluated echocardiographically before reoperation. Additionally, 263 of 446 patients (59%) with aortic bioprostheses and 42 of 74 patients (57%) with mitral bioprostheses who were alive in January 1993 had long-term echocardiographic follow-up.
Group A: Normally functioning bioprostheses were found in the aortic position in 242 of 263 patients and in the mitral position in 33 of 42 patients. Group B: Thirty patients had abnormal bioprosthetic function. Eleven patients had regurgitation, 3 had a combined lesion, and signs of calcification appeared in 16 patients with aortic valves, all with a peak gradient of above 60 mm Hg. Group C: Patients who had a reoperation (41 aortic and 10 mitral) within the follow-up period were followed up echocardiographically from the detection of a possible valve dysfunction until reoperation, and the findings accorded well with those at operation in 49 of 51 patients.
These findings suggest that, during a long-term follow-up, most bioprostheses function normally, facilitating improved heart function. Abnormalities in a bioprosthesis usually develop gradually, enabling their detection by Doppler echocardiographic evaluations performed regularly or in case of any symptomatic deterioration.
我们的目的是评估新一代猪源零压力固定生物心脏瓣膜(Biocor生物瓣膜)植入后(超过10年)的长期生物假体及心脏功能结果,以及确定超声心动图在选择需要再次手术的患者方面的准确性。目前缺乏使用这种生物瓣膜进行瓣膜置换术后的长期系统性多普勒超声心动图评估。
1983年1月至1993年1月期间,我们在主动脉瓣位(619例)或二尖瓣位(137例)植入了756个Biocor生物瓣膜。对随访期间接受再次手术的所有51例患者在再次手术前进行了超声心动图评估。此外,1993年1月仍存活的446例植入主动脉生物瓣膜患者中的263例(59%)和74例植入二尖瓣生物瓣膜患者中的42例(57%)进行了长期超声心动图随访。
A组:263例主动脉瓣位患者中有242例生物瓣膜功能正常,42例二尖瓣位患者中有33例生物瓣膜功能正常。B组:30例患者生物瓣膜功能异常。11例患者有反流,3例有复合病变,16例主动脉瓣患者出现钙化迹象,所有患者峰值压差均高于60 mmHg。C组:对随访期间接受再次手术的患者(41例主动脉瓣置换和10例二尖瓣置换)从检测到可能的瓣膜功能障碍直至再次手术进行超声心动图随访,51例患者中有49例的检查结果与手术时相符。
这些研究结果表明在长期随访期间,大多数生物瓣膜功能正常,有助于改善心脏功能。生物瓣膜异常通常是逐渐发展的,通过定期进行多普勒超声心动图评估或在出现任何症状恶化时进行评估能够检测到这些异常。